Aravive Inc

NASDAQ:ARAV   3:59:52 PM EDT
4.07
-0.22 (-5.13%)
Products

Aravive Announces Positive Initial Results From Phase 1B Portion Of The Phase1b/2 Study Of Avb-500 In Combination With Cabozantinib In Clear Cell Renal Carcinoma

Published: 06/24/2021 11:45 GMT
Aravive Inc (ARAV) - Aravive Announces Positive Initial Results From Phase 1b Portion of the Phase1b/2 Study of Avb-500 in Combination With Cabozantinib in Clear Cell Renal Carcinoma.
Aravive Inc - Avb-500 Was Well Tolerated With No Unexpected Findings.
Aravive Inc - Plans to Expand Dosing of 15mg/kg of Avb-500 to an Additional Three Patients.